City of Hope Researchers Target Cancer‑Specific PCNA Variant with Drug AOH1996
The challenge of targeting the DNA‑repair protein PCNA has long stymied oncology scientists because the molecule is required in every dividing cell, making direct inhibition toxic to healthy tissue. City of Hope investigators say they have sidestepped that obstacle by designing a small‑molecule inhibitor, AOH1996, that does not bind the native protein but instead recognizes an altered form found almost exclusively in malignant cells, which they term caPCNA.
The distinction between attacking the ubiquitous PCNA and the cancer‑restricted caPCNA is likened to the difference between a city‑wide bomb and a precision sniper round. AOH1996 works by slipping into cells and binding to caPCNA, thereby blocking its participation in the repair machinery.
City of Hope Researchers Target Cancer‑Specific PCNA Variant with Drug AOH1996
The difficulty of targeting the DNA‑repair protein PCNA has long frustrated cancer researchers because the molecule is essential for fixing damage in every dividing cell, and inhibiting it directly harms healthy tissue as well as tumors. City of Hope scientists claim they have circumvented this problem with an experimental drug called AOH1996.
Rather than attacking PCNA itself, AOH1996 seeks out a specific, altered version of the protein that appears almost exclusively in cancer cells, which the researchers have named caPCNA. They describe the selectivity as the difference between a bomb that levels an entire city block and a sniper round that takes out a single apartment. AOH1996 is a small‑molecule inhibitor designed to penetrate cells and bind to caPCNA, thereby blocking the cancer cell’s ability to repair its own DNA.
When this repair function is disabled, the malignant cell cannot divide, stalls and undergoes programmed death, while normal cells that rely on the unmodified PCNA remain unaffected. In laboratory tests, AOH1996 halted proliferation across a variety of cancer cell lines, induced cell‑cycle arrest and drove the cells into apoptosis.
The same assays performed on several normal, non‑malignant cell types showed no harm to those cells. Animal studies extended the findings: mice and dogs received doses six times higher than the effective amount and displayed no observable side effects or toxicity. Such a wide safety margin is uncommon; most cancer therapeutics, even those labeled targeted, possess a narrow therapeutic window that forces patients to trade quality of life for survival.
Phase I clinical trials of AOH1996 are now underway at City of Hope, focusing on solid tumors such as lung, breast, colon and pancreatic cancers. The primary goals of the trial are to assess safety and determine the optimal dosing regimen in humans, the first major step after years of pre‑clinical work.
Investigators are also exploring whether AOH1996 can be combined with existing chemotherapy agents. The rationale is that conventional chemotherapies damage DNA in all dividing cells; AOH1996 would then prevent cancer cells from fixing that damage, while normal cells retain their repair pathway. If successful, such a combination could increase efficacy while limiting adverse effects.
The name AOH1996 commemorates the patient whose tumor cells supplied the material used to develop the drug—a girl born in 1996 who later died of neuroblastoma; her cells continue to propagate in every batch of the compound. Researchers caution that positive pre‑clinical data do not guarantee success in humans.
Phase I trials frequently fail, and the transition from petri dish to patient is where many promising candidates falter.
